Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Recruiting · NCT06353906 · Registry updated 2025-12-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, penile cancer, penile disorder, penile neoplasm, squamous cell carcinoma of penis, urinary system disorder | Recruiting | Phase 2 | 2025-12-08 | NCT06353906 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| The Netherlands Cancer Institute | 113 |
2 results · Page 1 of 1